Meters & Strips($9B)

Lancets($1.3B)

Syringe($0.8B)

InsulinInhaler

Oral Anti-Diabetics(S-U, TZD,Met)

($30B)

GLP-1($1.7B)

Insulin($15B)

Patient CGM

($0.25B)

InsulinPumps

($0.75B)

Pro CGM

($0.02B)

POC A1C/ AG1,5

($0.3B)

DPP-4($6.8B)

Non-InvasiveGlucose

Meter

Scholz Consulting Partners LLC ° Diabetes Practice

• Continuous Glucose Monitoring • Non-invasive Glucose Monitoring• Glycemic Control in the ICU• Emerging therapies in T1DM• Oral, transdermal, and inhaled insulin• mHealth and remote monitoring

Bryce Sadybryce@scholzcp.com

Manfred Scholz, PhD, MBAms@scholzcp.com

Therapies Delivery DiagnosticsPens

($0.52B)

Selected Diabetes Markets and Companies

Oral/ Inhaled/Trans-dermal Insulin

ICU CGM

($0.15B)

Oral GLP-1

Ketone,µAlb

($0.2B)